Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Similar programs are offered by competing telehealth companies like Noom at comparable price points
As Fillit noted, GLP-1 drugs would be very good candidates to be delivered in combination with an anti-amyloid drug like Eisai and Biogens recently approved Leqembi (lecanemab) or Lillys investigational donanemab, because there is no overlap in the mechanism of action
Based on the strength of the clinical data, we expect Wegovy to be added to formularies with utilization management restrictions for prior authorization to prevent off-label use, shorter initial approval periods (e.g., six months approved initially) to ensure efficacy, and quantity limits to reduce stockpiling and waste
Some of that starts from real receptor biology and all of it ends well past what the evidence supports for a modified analog
doi: 10.1007/s12257-012-0623-z 111
